Raptor Pharmaceutical Inc. (RPTP) Announces Issuance of Key European Patent Protecting the Cysteamine Portfolio
7/30/2012 9:47:48 AM
NOVATO, Calif., July 30, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the European Patent Office has issued a key patent covering enteric-coated oral formulations of cysteamine bitartrate, including the Company's proprietary microbead formulation, RP103. Decision to Grant the patent was announced in July 2012. European Patent 1919458 covers the use of any composition of cysteamine or cystamine, regardless of the specific formulation, that provides increased delivery to the small intestine with pharmacokinetic benefits that allow for twice daily dosing in the treatment of nephropathic cystinosis. The European patent term will expire January 26, 2027.